Newron's Parkinson's Disease Drug Xadago Priced At $600-700/Month
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
You may also be interested in...
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.
Safinamide appears to be headed for a debut on the Indian market, after Sun Pharma received a go-ahead from a key expert panel for the Parkinson’s disease treatment. Pricing of the selective monoamine oxidase B inhibitor and innovator Newron’s stance around the emerging India activity for the product could be interesting to watch.